Polivy is an anti-CD79b antibody-drug conjugate (ADC). Polivy is currently approved in combination with bendamustine plus rituximab in more than 70 countries worldwide, including in the EU and in the US. In the US, Polivy in combination with bendamustine plus rituximab for the treatment of adults with relapsed or refractory, who have received at least two prior therapies, and in Europe for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not candidates for a haematopoietic stem cell transplant.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals and patients are asked to report any suspected adverse reactions.
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.